nach oben

Current Dermatology Reports

Erschienen in:

01.12.2014 | Pediatrics (R Sidbury, Section Editor)

What’s New in Pediatric Dermatology

verfasst von: Kate Khorsand, Sam Backus, Robert Sidbury

Erschienen in: Current Dermatology Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Clinical guidelines relating to atopic dermatitis, systemic beta-blockade for infantile hemangiomas and acne have all been published within the last 2 years. Important studies have also better characterized emerging infections such as coxsackievirus a6, mycosis fungoides, severe cutaneous drug reactions in the pediatric population, and hidradenitis suppurativa; these will all be reviewed here.

Eichenfield LE, Tom WT, Chamlin S, et al. Guidelines atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51.PubMedCrossRef

Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–60.PubMedCrossRef

Ring J, Alomar A, Deleuran M, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176–93.PubMedCrossRef

Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465–73.PubMedCrossRef

Leaute-Labreze C, Dumas de la Rogue E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.PubMedCrossRef

Lou Y, Peng WJ, Cao Y, et al. The effectiveness of propranolol in treating infantile hemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78(1):44–57.PubMedCrossRef

Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.PubMedCentralPubMedCrossRef

Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131:163–86.CrossRef

Lam J, Pope E. Pediatric pityriasis lichenoides and cutaneous T cell lymphoma. Curr Op in Pediatr. 2007;19:441–5.CrossRef

10.

Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer. 1999;85:208–11.PubMedCrossRef

11.

Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240–4.PubMedCentralPubMedCrossRef

12.

Slater D. The new world health organization-european organization for research and treatment of cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153:874–80.PubMedCrossRef

13.

Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21:525–33.PubMedCrossRef

14.

Boos M et al. PL and MF: an update on the diagnosis of the most benign and malignant lymphoproliferative disorders in childhood. Curr Ped Rep 2013, Springer

15.

Hodak E, Amitay-Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol. 2014;70:993–1001.PubMedCrossRef

16.

Laws PM, Shear NH, Pope E. Childhood Mycosis Fungoides: experience of 28 patients and response to phototherapy. Peds Derm. 2014: 1–6.

17.

Atanaskovic-Markovic M, Medjo B, Gavrovic-Jankulovic M, Cirkovic Velvckovic T, Nikolic D, Nestorovic B. Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatr Allergy Immunol. 2013;24(7):645–9.PubMedCrossRef

18.

Finkelstein Y, Macdonald EM, Li P, Hutson JR, Juurlink DN. Recurrence and mortality following severe cutaneous adverse reactions. JAMA. 2014;311(21):2231–2.PubMedCrossRef

19.

Wong S, Koh M. PD33-drug reaction and eosinophilia with systemic symptoms (DRESS): a 10-year review in a pediatric population. Clin and Transl Allergy. 2014;4 Suppl 1:33.CrossRef

20.

Chong K, Chan D, Cheung Y, Ching L, Hie S, Thomas T, et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B* 1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child. 2014;99:581–4.PubMedCrossRef

21.

Amstutz U, Shear N, Rieder M, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B* 15: 02 and HLA-A* 31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55(4):496–506.PubMedCrossRef

22.

MMWR Morb Mort Weekly Rep Notes from the field: Severe hand foot and mouth disease associated with coxsackie A6 Alabama, Connecticut, California, Nevada November 2011-February 2012. 2012 Mar 30;61(12):213–4.

23.

Mathes EF, Oza V, Frieden IJ, et al. Eczema coxsackium and unusual cutaneous findings in an enterovirus outbreak. Pediatrics. 2013;132:e149–57.PubMedCentralPubMedCrossRef

24.

Gold DA, Reeder VJ, Mahan M, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703.PubMedCrossRef

25.

Machet L, Samimi M, Delage M, et al. Systematic review of the efficacy and adverse events associated with infliximab treatment of HS in patients with co-existent inflammatory diseases. J Am Acad Dermaol. 2013;69(4):649–50.CrossRef

26.

Randhawa HK et al. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Derm. 2013;149(6):732–5.CrossRef

27.

Zarchi K et al. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Derm. 2013;149(10):1192–4.CrossRef

Titel: What’s New in Pediatric Dermatology
verfasst von: Kate Khorsand
Sam Backus
Robert Sidbury
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2014
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-014-0091-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

What’s New in Pediatric Dermatology

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Pathomechanisms of Chronic Spontaneous Urticaria: What Is Known and Up to Date

Alternative Medicine in Pediatric Dermatology: What Is the Evidence?

Pediatric Dermatology Clinical-Pathologic Cases: A Spectrum of Purpuric Disorders of Childhood

The Third Chair in the Examination Room: Practical Ethics of Decision-Making for the Pediatric Dermatologist

Diagnostic Imaging and Image-Guided Therapy for Hemangiomas and Vascular Malformations: What the Dermatologist Needs to Know

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie